Ann: Appendix 4C - quarterly , page-8

chookman you keep calling this under 2c in the face of continued positive news - don't understand your justification nor do I see it happening

CandN1986 the way I understand it is the Brazilian company have likely seen the product through their negotiations with the South Partners, see its potential and are currently moving towards regulatory approval and a distribution agreement. The hospital trials would be a natural step in this process one would think. As they said in the quarterly, the LOI is a huge positive, but the signed distribution agreement will bring the real rerate.

timely1 I was referring to the ALTO's that have expired - they had a 4c exercise price. Had we not run into those delays and supply issues then I think they would have had a real chance of being in the money and getting converted. What would be good is to see a reduced amount of similarly priced options perhaps re-offered to all holders again, maybe by way of SPP ? One thing we know is they have always looked after holders in the past and never been one to do heavily discounted placements to friendlies - rights issues and SPP are definitely the best for shareholders.

IMO, all should send their thoughts / queries to the company as we are all expecting an update in the next week or so, so they may use that as an opportunity to address them.